Back

CEASE AF: Primary Efficacy and Safety Endpoints

17 April 2023 (14:00 - 14:10)
Organised by:
Congress Presentation Part of: Late Breaking Science - Day 2 Rhythm Control, Hybrid Therapy EHRA Premium Access EHRA 2023

About the speaker

Photo
Professor Nicolas Doll

Schuechtermann-Clinic, Bad Rothenfelde (Germany)

7 More presentations in this session

Presentation thumbnail
AdaptResponse: A randomized study of synchronized LV pacing
Professor B. Wilkoff (Cleveland, US)
Slides Video
Presentation thumbnail
AdaptResponse: A randomized study of synchronized LV pacing - discussion
Professor J. Steffel (Zurich, CH)
Slides Video
Presentation thumbnail
Extended ECG monitoring in HCM
Mr J. Caro Codon (Madrid, ES)
Slides Video
Presentation thumbnail
Extended ECG monitoring in HCM - discussion
Professor I. Van Gelder (Groningen, NL)
Slides Video
Presentation thumbnail
AIDEG-VTA - ICD EG during VT ablation
Professor J. Almendral Garrote (Boadilla del Monte, ES)
Slides Video

Access the full session

Session thumbnail
Late Breaking Science - Day 2
Video

The Event

Event poster

EHRA 2023

17 April 2023 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Hybrid AF ablation: EP meets the surgeon
thumbnail
Congress Presentation
Three-year safety and effectiveness of Hybrid Ablation versus Catheter Ablation: Final results of the CEASE-AF trial
thumbnail
Congress Presentation
Two-year safety and effectiveness of hybrid ablation versus catheter ablation in patients with non-paroxysmal AF: mid-term results of the CEASE-AF trial

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources